Skip to main content

Monopar Therapeutics, Inc. (MNPR)

NASDAQ: MNPR · IEX Real-Time Price · USD
5.13 0.07 (1.38%)
Sep 24, 2021 12:41 PM EDT - Market open
Market Cap63.67M
Revenue (ttm)n/a
Net Income (ttm)-7.73M
Shares Out12.57M
EPS (ttm)-0.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,828
Open5.05
Previous Close5.06
Day's Range5.01 - 5.14
52-Week Range4.28 - 17.01
Betan/a
AnalystsBuy
Price Target33.25 (+548.1%)
Est. Earnings DateNov 11, 2021

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, wh...

IndustryBiotechnology
IPO DateDec 19, 2019
Employees9
Stock ExchangeNASDAQ
Ticker SymbolMNPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is 33.25, which is an increase of 548.15% from the latest price.

Price Target
$33.25
(548.15% upside)
Analyst Consensus: Buy

News

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sa...

WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend ...

1 week ago - GlobeNewsWire

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021 Validive ® Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022

1 month ago - GlobeNewsWire

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

1 month ago - GlobeNewsWire

Monopar Stock Gains On Launch Of Early Stage Soft Tissue Cancer Trial With Camsirubicin

The FDA has signed off Monopar Therapeutics Inc's (NASDAQ: MNPR) IND to commence an open-label Phase 1b dose-escalation trial to evaluate camsirubicin plus pegfilgrastim in patients with advanced soft t...

1 month ago - Benzinga

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

1 month ago - GlobeNewsWire

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MAS...

WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

3 months ago - GlobeNewsWire

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University ...

Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline

3 months ago - GlobeNewsWire

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

First Patient Dosed in Validive ® Phase 2b/3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Su...

4 months ago - GlobeNewsWire

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes announced a corporate update describing progress in its key programs during the past year and upcoming milestones.

5 months ago - Business Wire

Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer

Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could poten...

5 months ago - Benzinga

Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed ...

5 months ago - GlobeNewsWire

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates

Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer

5 months ago - GlobeNewsWire

Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Canc...

- Initial focus on use in bladder cancer surgery - Initial focus on use in bladder cancer surgery

6 months ago - GlobeNewsWire

Monopar Therapeutics to Present at Upcoming Investor Conferences

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

7 months ago - GlobeNewsWire

Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemor...

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

7 months ago - GlobeNewsWire

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Out...

WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

7 months ago - GlobeNewsWire

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed t...

7 months ago - GlobeNewsWire

Why Monopar Therapeutics And EyePoint Pharma Are Trading Higher Today

Monopar Therapeutics (NASDAQ: MNPR) shares are trading higher Thursday after Roth Capital initiated coverage on the stock with a Buy rating and a price target of $49 per share. Monopar Therapeutics is a...

7 months ago - Benzinga

Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%

Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

-Issued patent expands and strengthens Monopar's existing camsirubicin IP portfolio -Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021 

9 months ago - GlobeNewsWire

Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19

WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen...

9 months ago - GlobeNewsWire

Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradioth...

There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM

9 months ago - GlobeNewsWire

Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

Validive ® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021

10 months ago - GlobeNewsWire

Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate...

Strengthens Monopar's Validive IP Portfolio To 2035 Strengthens Monopar's Validive IP Portfolio To 2035

10 months ago - GlobeNewsWire

Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at t...

1 year ago - GlobeNewsWire